Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023
AUSTIN, TX and DURHAM, NC, Dec. 05, 2023 -- Shattuck Labs, Inc. , a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic...
Source: marketscreener.com
